 Home > Medical News > Latest Medical News > The second batch of national key monitoring and rational drug use drugs catalogue was issued

The second batch of national key monitoring and rational drug use drugs catalogue was issued

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

3 8 7 16

dpt drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Health commissions of all provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps:

In order to further strengthen the management of clinical rational drug use in China, according to the "National Key Monitoring Rational Drug List Adjustment Work Regulations" (National Health Office Medical Letter [2021] No.
474), our committee determined the "Second Batch of National Key Monitoring and Rational Drug Use Drug List" (hereinafter referred to as the "Catalogue"
).
It is now issued to you for use in strengthening the management of rational drug use and carrying out performance appraisal of public hospitals
.

All localities should take standardizing clinical drug use behavior and promoting rational drug use as the work goal, formulate and improve clinical application guidelines for drugs included in this catalog, clarify the conditions and principles for clinical application, and strengthen the supervision
of rational drug use.
Where the drugs in the First Batch of Catalogue of Drugs for Rational Use of National Key Monitoring (Guo Wei Ban Medical Letter [2019] No.
558) are included in this Catalogue, key monitoring shall be strengthened in accordance with requirements; Those that are not included in this Catalogue shall be continuously monitored for at least one year after they have been continuously monitored, so as to promote the continuous improvement
of the level of clinical rational drug use.

General Office of the National Health Commission

January 13, 2023

(Information disclosure form: active disclosure)

The second batch of national key monitoring and rational drug use drug list

1	Omeprazole
2	Human blood albumin
3	Cefoperazone sulbactam
4	Edaravone
5	Ginkgo biloba extract
6	Pantoprazole
7	Compound amino acids
8	Dezocine
9	Betaxistine
10	Budesonide
11	niacinamide
12	Ceftalidime
13	Piracillin, tazobactam
14	Esomeprazole
15	Piracetam
16	Levofloxacin
17	Famotidine
18	Oxiracetam
19	Rabeprazole
20	Prostadil
21	Bone peptides
22	Papaverine
23	nicotinic acid
24	Acetylglutamine
25	Lansoprazole
26	Brain protein hydrolysates
27	Meropenem
28	Creatine phosphate
29	Monosialic acid tetrahexose gangliosides
30	Ceftaxime

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.